Loading data for ACRS — first visit, this takes a few seconds.

알림

Aclaris Therapeutics Inc. (ACRS)

NasdaqGS: ACRS · 실시간 가격 · USD

6.30

+0.38 (6.42%)

종가 기준: Aug 21, 2026, 8:00 PM

6.42

+0.13%

애프터마켓: 4:41 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

6.42% (1D)

데이터 없음

매수호가	6.27
시가총액	943.54M
매출 (ttm)	8.22M
순이익 (ttm)	-75.74M
	0.78
	-0.58
	n/a
	-7.89
P/B (ttm)	7.19
P/S (ttm)	114.80
실적 발표일	Nov 5, 2026

매도호가	7.2
거래량	1,995,668
평균 거래량 (20일)	1,771,367
시가	5.88
전일 종가	5.92
일중 범위	5.85 - 6.32
52주 범위	1.74 - 6.51
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

ACRS 소개

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to s...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Oct 6, 2015

직원 수 69

상장 거래소 NasdaqGS

티커 ACRS

웹사이트 https://www.aclaristx.com

전체 기업 정보

재무 실적

2025년 Aclaris Therapeutics의 매출은 7.83M로, 전년 18.72M 대비 -58.19% 감소했습니다. 순이익은 -64.92M로, -50.84% 감소했습니다.

재무제표

어닝 서프라이즈

Aclaris Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $1.63M 예상치 하회 $0, 및 -8.33% 전년 대비 감소.
EPS -0.15 예상치 상회 0.01, 및 -15.38% 전년 대비 감소.

다음 실적 발표

Aclaris Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Zacks

Wall Street Analysts Believe Aclaris (ACRS) Could Rally 69.2%: Here's is How to Trade

The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

2주 전 · Zacks

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of +6.25% and +17.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1개월 전 · Zacks

Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?

Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa...

2개월 전 · MarketBeat

3 Penny Stocks Under $5 Backed by Real Revenue Growth

These three penny stocks under $5 generate real revenue and have catalysts that analysts believe could drive significant upside

2개월 전 · Insider Monkey

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

Aclaris Therapeutics Inc. (NASDAQ:ACRS) is one of the top penny stocks to buy in investors’ stock portfolio. On May 8, Stifel reiterated a Hold rating on Aclaris Therapeutics Inc. (NASDAQ:ACRS) and in...

2 페이지 중 1

Aclaris Therapeutics Inc. (ACRS)